AB Science

AB Science SA is a pharmaceutical company specializing in drugs that use tyrosine kinase inhibitors. It was founded in 1999.In April 2023, AB Science SA announced successful capital increase through private placement for 15.0 million euros.In December 2022, AB Science SA received payment of €6.0 million as the first tranche of a €15 million loan from European Investment Bank.In February 2022, AB Science SA announced that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants.In October 2020, AB Science announced the agreement with qualified investors on a financing of Euro 4.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants.In March 2020, the company raised gross proceeds of EUR 6.40 million (US $7.05600 million) in a private placement of 860,220 new ordinary shares at EUR 7.44 (US $8.20260) per sha